 |
|
|
| |
PATIENT-REPORTED OUTCOMES ON LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: FLAIR 96-WEEK RESULTS
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Vasiliki Chounta,1 Enrique Bernal,2 Johan Lombaard,3 Harold Katner,4 Sharon Walmsley,5 David Dorey,6 William R. Spreen,7 Sandy Griffith,7 David A. Margolis7
1ViiV Healthcare, Brentford, UK; 2Hospital Reina Sofía, Murcia, Spain; 3Josha Research, Bloemfontein, South Africa; 4Mercer University School of Medicine, Macon, GA, USA; 5University Health Network, Toronto, ON, Canada; 6GlaxoSmithKline, Mississauga, ON, Canada; 7ViiV Healthcare, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
